Whalegun
Home

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $40K for lobbying in Q3 2023 · Health Issues

Trade details

Type
Lobbying report
Amount
$40,000
Quarter
Q3 2023
Stock
Ultragenyx Pharmaceutical RARE
Client
Ultragenyx Pharmaceutical
Reported
23/10/17

Down 33.3% from last quarter

What else happened in Ultragenyx Pharmaceutical around then

Filed or reported within 30 days of the trade day · 23/08/31~23/10/30

Ultragenyx Pharmaceutical's other lobbying reports

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $40K for lobbying in Q3 2023 · Health Issues | Whalegun